Back to search results

EXoPERT EMERALD Clinical Study for Cancer Detection

This study, called EXoPERT EMERALD, is looking for people aged 45 or older who have been diagnosed with or are suspected of having lung, breast, colorectal, pancreatic, or ovarian cancer. The goal is to collect blood samples before any cancer treatment begins. Researchers will use these samples to develop and test an artificial intelligence (AI) software called EXoPred. This software analyzes tiny particles in your blood called extracellular vesicles (EVs) to see if it can accurately detect these cancers early. The study will measure how well the EXoPred test works and if enough usable samples are collected over up to 36 months. The study is currently unclear on its recruitment status and plans to enroll 1400 participants.

Study design
This is an observational study that aims to collect blood samples to develop and evaluate an AI-based diagnostic software. It involves three phases to train and test the software using a total of at least 750 samples.
What's involved
The study involves providing a blood sample before starting any cancer treatment. The exact number of visits or procedures beyond this initial sample collection is not specified.
Compensation
Not stated in the trial record.
Follow-up
Your samples will be used for evaluation for up to 36 months from the date of enrollment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07186296

EXoPERT EMERALD Clinical Study

Recruiting
Not specifiedAges 45+Observational
EXoPERT
~1,400 participants
Updated 2026-07-01 on ClinicalTrials.gov
What's tested:EXoPred

At a glance

Recruiting sites
9 of 9 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Test Sufficient Samples
Measured over From date of enrollment up to 36 months
+1 more outcome measured

Conditions

Breast Cancer
Colon Cancer
Pancreatic Cancer
Ovarian Cancer
Lung Cancer

Explore related trials

Breast CarcinomaColorectal CarcinomaLung CarcinomaMalignant Ovarian NeoplasmPancreatic CarcinomaSolid Neoplasm

Where it's being run

9 sites across 5 states
New York3
California2
Kentucky2
Hawaii1
Maryland1

Study leadership

  • Jonathan Dudley, MD · PRINCIPAL_INVESTIGATOR · Johns Hopkins University
  • Saeed Jortani, Ph.D. · PRINCIPAL_INVESTIGATOR · Kentucky Clinical Trial Laboratory

Who to contact

Young Park
[email protected]
(+82) 02 923 8833
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Subject aged 45 years or older with a biopsy-proven or clinically suspected primary lung, breast, colorectal, pancreatic, or ovarian cancer, based on objective findings such as radiological, serological, endoscopic, or cytological findings, whose blood was collected prior to any systemic or definitive therapy for the cancer.
Subjects who are willing and able to provide written informed consent.
Subjects who are willing and able to comply with the study requirements.

Exclusion

Any history of cancer diagnosed and treated within 5 years prior to the date of consent.
Subjects with a history of previous cancer treatment via surgical resection, hormonal cancer treatment, chemotherapy, radiotherapy within the past 6 months for recent cancer diagnosis.
Subjects who have any history of an allogeneic bone marrow, stem cell transplant, or solid organ transplant.
Subjects who are pregnant or breastfeeding women.
Subjects who have consented and have undergone treatment in any other cancer related clinical trials withinthe past 6 months.
Subjects who are currently in active treatment for drug abuse.
Subjects who have received any treatment related to lung, breast, colorectal, pancreatic, or ovarian nodules, such as hormones prior to entering the study.
Unsuitable sample for testing due to contamination, hemolysis, etc.

What this trial measures

  • Test Sufficient SamplesFrom date of enrollment up to 36 months

    Test sufficient samples from 5 cancers to lock an validate algorithm to support future clinical study.

  • Evaluate PerformanceFrom date of enrollment up to 36 months

    Test performance: diagnosis of multiple cancer, assessed by sensitivity. Test performance: diagnosis of multiple cancer, assessed by specificity. Test performance: diagnosis of multiple cancer, assessed by tissue of origin (TOO) accuracy.